Esophageal cancer secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
*In 1983, a study was carried out in Hishun village, China. | |||
*Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high. | |||
*6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium. | |||
*Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo. | |||
*The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo. | |||
*They took their respective treatments for 3 years and were then reexamined using cytology. | |||
*The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%). | |||
*The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups. | |||
*These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 15:25, 11 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer secondary prevention |
|
Risk calculators and risk factors for Esophageal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.
Secondary Prevention
- In 1983, a study was carried out in Hishun village, China.
- Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
- 6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium.
- Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
- The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
- They took their respective treatments for 3 years and were then reexamined using cytology.
- The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
- The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups.
- These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.[1]